Study #2024-0509
A phase 2 study evaluating olutasidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic/syndromes/chronic myelomonocytic leukemia.
MD Anderson Study Status
Enrolling
Treatment Agent
Olutasidenib
Description
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Study phase:
Phase II
Physician name:
Kelly Chien
Department:
Leukemia
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.